September 20th 2024
The approval of amivantamab plus carboplatin and pemetrexed is supported by data from the phase 3 MARIPOSA-2 trial.
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Treatment Strategies With NTRK Gene Rearrangements Emerge in Lung and Other Solid Tumors
September 4th 2015The standard of care for lung cancers has been dramatically transformed by the growing availability of molecular diagnostics and genetic testing, and by targeted therapies that specifically inhibit a number of well-established oncogenic drivers.
Read More
New York Lung Cancer Conference to Prominently Feature Immunotherapy and Targeted Therapies
August 10th 2015On November 7, 2015, some of the leading experts in oncology, together with other oncology healthcare professionals involved in the treatment and management of patients with lung cancer, will gather in Manhattan for the 10th Annual New York Lung Cancer Symposium®.
Read More
Underused Ovarian Cancer Treatment Improves Overall Survival
August 7th 2015Almost 10 years following a study that proved intraperitoneal (IP), or abdominal, chemotherapy, along with intravenous (IV) therapy, may add 16 months or more to the lives of women with ovarian cancer, less than half of these patients at US hospitals receive this type of treatment
Read More
Translational Advances Deliver Precision Medicine to NSCLC
August 5th 2015Precision medicine with TKIs and immunotherapies is revolutionizing the treatment of patients with NSCLC. Paul A. Bunn, Jr, MD, head of the Division of Medical Oncology at the University of Colorado, discussed the current translational advances with these agents in a discussion held at this year’s International Lung Cancer Congress.
Read More
New Trial Designs Hope to Improve the Discovery of Biomarkers in NSCLC
August 5th 2015Clinical trial designs are experiencing a huge transformation geared toward the discovery and confirmation of new predictive biomarkers for patients who have non-small cell lung cancer (NSCLC), as well as other types of solid tumors.
Read More
Radiation Therapy Dose for the Treatment of Patients With Lung Cancer
August 4th 2015Walter J. Curran, Jr., MD, FACR, associate vice president of cancer, Woodruff Health Sciences Center, executive director, Winship Cancer Institute, Lawrence W. Davis Chair of Radiation Oncology, Emory University, discusses radiation therapy dose for the treatment of patients with lung cancer.
Read More
Rociletinib NDA Completed by Clovis Oncology for EGFR T790M-positive NSCLC
August 4th 2015A new drug application (NDA) was recently submitted for rociletinib (CO-1686) as a treatment for patients who have EGFR T790M-positive metastatic non-small cell lung cancer (NSCLC) following previous administration of an EGFR TKI.
Read More
Combinations of Checkpoint Inhibitors Under Investigation in NSCLC
August 4th 2015After a successful demonstration as single-agents, clinical trials are currently assessing PD-1 and PD-L1 inhibitors, combined with chemotherapy, targeted therapies, and radiation therapy, in an attempt to further improve outcomes for patients who have non-small cell lung cancer (NSCLC).
Read More
SBRT in Surgery for Patients With Early NSCLC
August 3rd 2015Roy Decker, MD, PhD, associate professor of therapeutic radiology, assistant professor of surgery (Otolaryngology), Clinical Research Program Leader, Therapeutic Radiology, Yale University, discusses stereotactic body radiation therapy (SBRT) in surgery for patients with early non-small cell lung cancer (NSCLC).
Read More
Clinical Trials in EGFR-Mutant NSCLC Hasten Precision Medicine Initiatives
July 31st 2015In addition to late patient presentation, the high mortality rate in lung cancer can be largely attributed to the complex nature of the disease and a very high rate of heterogeneity in the causative molecular abnormalities.
Read More
Immunotherapy Versus Targeted Therapy - Which Has Greater Impact in NSCLC?
July 30th 2015Immunotherapies (immune checkpoint inhibitors) and targeted therapies (tyrosine kinase inhibitors [TKIs] that target specific mutations in one or more oncogenic drivers) represent two of the most researched types of therapy under investigation for the treatment of non-small cell lung cancer (NSCLC).
Read More
New Genome Characterization Center to Focus on Proteomics Across Tumor Types
July 27th 2015The University of Texas MD Anderson Cancer Center in Houston has been selected as the site for one of two new Genome Characterization Centers (GCCs) funded by the National Cancer Institute (NCI) and National Institute of Health (HHSN261200800001E).
Read More
Breakthrough Designation Granted to BRAF/MEK Combo for BRAF V600 NSCLC
July 23rd 2015Breakthrough therapy designation has been granted by the US Food and Drug Adminstration (FDA) to the combination of the BRAF inhibitor dabrafenib (Tafinlar) and the MEK inhibitor trametinib (Mekinist) as treatment for patients with BRAF V600E-mutant non–small cell lung cancer
Read More
Cabozantinib (Cometriq) Improves PFS and OS in Patients With mRCC
July 20th 2015Results from the phase III METEOR study showed that treatment with cabozantinib (Cometriq) improved progression-free survival (PFS) and overall survival (OS) compared with everolimus (Afinitor) in previously treated patients with metastatic renal cell carcinoma (mRCC).
Read More
Gefitinib (Iressa) FDA Approved in Patients With EGFR-Positive NSCLC
July 14th 2015Gefitinib (Iressa) was recently approved by the FDA for the frontline treatment of patients who have metastatic, EGFR-positive non-small cell lung cancer (NSCLC) with an exon 19 deletion or exon 21 (L858R) substitution.
Read More
Effect of Anamorelin on Cachexia in Advanced NSCLC
June 18th 2015Jennifer S. Temel, clinical director, Thoracic Oncology, Massachusetts General Hospital, discusses a phase III study that examined the impact of anamorelin in patients with advanced non-small cell lung cancer (NSCLC) and cachexia.
Watch
Early Detection of Resistance in Lung Cancer Detected Through ctDNA in Urine
June 17th 2015An assay that measures circulating tumor (ct) DNA in the urine can detect the early acquisition of epidermal growth factor receptor (EGFR) resistance mutations in patients with metastatic lung adenocarcinoma.
Read More
Accurate Blood Test for Diagnosis of Lung Cancer Could Save Lives
June 12th 2015Researchers at the Wistar Institute Cancer Center have discovered a new potential circulating biomarker for non–small cell lung cancer. It is a cancer testis antigen expressed by a cancer/testis gene called AKAP4. The exciting prospect this heralds is the development of an accurate, quick blood test for early-stage NSCLC.
Read More